The International Autoimmune Hepatitis Group

Size: px
Start display at page:

Download "The International Autoimmune Hepatitis Group"

Transcription

1 Diagnostic Value and Utility of the Simplified International Autoimmune Hepatitis Group (IAIHG) Criteria in Acute and Chronic Liver Disease Andrew D. Yeoman, Rachel H. Westbrook, Thawab Al-Chalabi, Ivana Carey, Nigel D. Heaton, Bernard C. Portmann, and Michael A. Heneghan Diagnostic criteria for autoimmune hepatitis (AIH) have been created and revised by the International Autoimmune Hepatitis Group (IAIHG). Simplified criteria have been created, but remain independently unvalidated. We report on the diagnostic accuracy of the simplified criteria in patients across a range of diagnoses, including a subset of patients presenting with fulminant liver failure who required liver transplant. Patients with AIH and non-aih etiologies of liver disease were identified from dedicated patient databases. Parameters relevant to the simplified and 1999 IAIHG criteria were recorded, and sensitivity, specificity, and positive and negative predictive values for scores of >6 (probable AIH) and >7 (definite AIH) were calculated. A total of 549 patients with chronic liver disease were evaluated, (221 with AIH, 26 with variant syndromes, and 302 with non-aih). For scores >6, sensitivity was 90%, and specificity was 98% with positive and negative predictive values of 97% and 92%, respectively. For scores >7; sensitivity was 70%, and specificity was 100% with positive and negative predictive values of 100% and 74%, respectively. Seven false positive diagnoses of AIH occurred, all with simplified scores of 6. Concordance with 1999 criteria was 90% for probable and 61% for definite AIH. The frequency of an overall diagnosis of AIH (probable or definite AIH) among the 70 patients with fulminant liver failure was 24% for simplified criteria and 40% for 1999 criteria, respectively. Conclusion: The simplified criteria retain high specificity but exhibit lower sensitivity for scores of >7. The explanations for this are unclear but may relate to loss of such discriminating information as response to corticosteroids. Prospective evaluation of these criteria is required to corroborate these observations. (HEPATOLOGY 2009;50: ) The International Autoimmune Hepatitis Group (IAIHG) was conceived in 1993, consisting of experts in the field of autoimmune liver disease. Convened originally to develop criteria to aid in the diagnosis of autoimmune hepatitis (AIH) that would be useful Abbreviations: AIH, autoimmune hepatitis; ALD, alcoholic liver disease; AUC, area under the curve; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV, hepatitis C virus; IAIHG, International Autoimmune Hepatitis Group; IgG, immunoglobulin G; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; ROC, receiver operating characteristic. From the Institute of Liver Studies, King s College Hospital NHS Foundation Trust, London, UK. Received January 23, 2009; accepted April 14, Address reprint requests to: Dr. Michael A. Heneghan, Institute of Liver Studies, King s College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK. michael.heneghan@kch.nhs.uk; fax: Copyright 2009 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. in clinical practice (distinguishing chronic active hepatitis related to hepatitis C virus [HCV] infection from that of a true autoimmune etiology) and to allow comparison between patients in trials of AIH, these criteria were widely accepted and incorporated into clinical practice in both nontransplant 1-5 and transplant settings. 6,7 The initial deliberations led to diagnostic criteria that defined individuals into one of three categories: not AIH, probable AIH, and definite AIH. 1 Although cumbersome, when applied, these criteria could be used to diagnose AIH with a high degree of sensitivity, albeit with a lower specificity. Prospective validation of these cohorts suggested a sensitivity for the diagnosis of AIH of between 97% and 100%. 2-4 Over time, it became evident that patients with other autoimmune liver conditions such as primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC) could be ascribed a false positive diagnosis of AIH. Therefore, a desire arose, not just to give the criteria greater specificity, but also to allow easier imple- 538

2 HEPATOLOGY, Vol. 50, No. 2, 2009 YEOMAN ET AL. 539 Table 1. Original Revised (1999) Criteria for the Diagnosis of AIH Parameter/Discriminator Score Female sex ALP:AST (or ALT) ratio Serum globulins or IgG above normal ANA, SMA, or LKM-1 1:80 1:80 1:40 1 1:40 0 AMA-positive 4 Hepatitis viral markers Positive Negative Drug history Positive 4 Negative 1 Average alcohol intake 5 g/day 60 g/day Liver histology Interface hepatitis Predominantly lymphoplasmacytic infiltrate Rosetting of liver cells 1 None of the above 5 Biliary changes Atypical features Other autoimmune disease(s) in either patient or first-degree relative Optional additional parameters Seropositivity for other defined antibodies HLA DR3 or DR4 1 Response to therapy Remission alone Remission with relapse Interpretation of aggregate scores Pretreatment: Definite AIH 15 Probable AIH Posttreatment: Definite AIH 17 Probable AIH Adapted from Alvarez et al. 5 mentation in clinical, rather than research, practice. This led to a revision of the original criteria in These revised criteria proposed modification of the scores allocated to the presence, or otherwise, of cholestatic liver function tests, drug history, liver histology, and response to treatment. The original revised, and widely applied, IAIHG criteria for the diagnosis of AIH are summarized in Table 1. The revised score, although a useful adjunct to the diagnosis of AIH in cases with atypical features, remained cumbersome due to the sheer number of variables (n 12) analyzed, which led to criticism of its application. Furthermore, the diagnosis of AIH continued to be challenging, especially in patients with atypical histological, biochemical, and immunological features. Consequently, the IAIHG group have recently streamlined the diagnostic criteria, with a sharp focus on the clinical diagnosis of AIH, and the aim of making them readily usable at the bedside. 8 As a result, the new, simplified criteria incorporates only four parameters: presence of associated autoantibodies, immunoglobulin G (IgG) level, liver histology, and the absence of viral hepatitis. The reduction in number of parameters analyzed was based on the outcomes of stepwise logistic regression which identified the above features, when combined, as having the greatest predictive value for the diagnosis of AIH with an area under the curve (AUC) on receiver operating characteristic (ROC) of The simplified IAIHG criteria for the diagnosis of AIH are summarized in Table 2. Currently, in this new system, a score of 6 (8 being maximum) equates to probable AIH whereas a score of 7 or above denotes definite AIH. The specificity of this score in the training and validation sets obtained from retrospective analysis of a multinational cohort is 97% for a probable diagnosis and 99% for a definite diagnosis of AIH. Meanwhile, sensitivity was reported as 88% for probable and 81% for a definite diagnosis of AIH using these criteria. What remains uncertain, however, is whether these criteria remain reproducible outside of the IAIHG multinational patient cohort, although a recent publication has described performance characteristics of the score in a series which contributed to the cohort used in the development of the simplified criteria. 9 We therefore set out to examine the validity and utility of the new simplified IAIHG diagnostic criteria and make an assessment of its Table 2. Simplified Diagnostic Criteria for the Diagnosis of AIH Parameter Discriminator Score ANA or SMA 1:40 1 ANA or SMA 1:80 or LKM 1:40 or SLA Positive IgG Level Upper limit of normal Upper limit of normal Liver Histology Compatible with AIH 1 Typical of AIH Absence of Viral Hepatitis No 0 Yes Adapted from Hennes et al. 8 6 points: Probable AIH 7 points: Definite AIH

3 540 YEOMAN ET AL. HEPATOLOGY, August 2009 sensitivity and specificity in the diagnosis of AIH both in comparison to the IAIHG simplified criteria and also to the original, revised criteria published in In addition, it is not known how many patients (if any) in the simplified IAIHG criteria presented with fulminant hepatic failure (FHF) and, although this group represents a relatively infrequent presentation of AIH, these patients present difficult challenges diagnostically. Therefore, it is of interest to assess the utility of the simplified criteria in this patient group. Indeed, work from our own institution, among others, suggests that features of autoimmunity (such as autoantibodies) are a frequent finding in patients with FHF despite the absence of classical clinical features of AIH Consequently, the utility of the simplified diagnostic criteria in this setting has not been established. Moreover, if it was possible to aid the early identification of an autoimmune etiology of FHF, prompt treatment might improve clinical outcome and prevent the need for liver transplantation. Patients and Methods Patients with AIH were identified from a dedicated database, collected prospectively since 1971, and continuously updated. Patients with other liver diagnoses (hepatitis B virus [HBV] and HCV infection, PSC, PBC, hemochromatosis, Wilson s disease, drug-induced liver injury, nonalcoholic steatohepatitis [NASH], alcoholic liver disease [ALD], PBC/AIH overlap [variant], and PSC/AIH overlap [variant] syndromes) were also retrospectively identified from the Institute of Liver Studies, Liver Database. All diagnoses were made via standard clinical criteria and, for drug-induced liver injury, by exclusion of all other causes in patients exposed to known hepatotoxic agents. For the cohort with non acetaminophen induced liver failure, individuals were retrospectively identified from a dedicated database of patients who underwent transplantation at King s College Hospital, National Health Service Foundation Trust, London, UK. Individuals who underwent transplantation were chosen because the majority with this mode of presentation do not have a liver biopsy before transplant due to the risk of hemorrhage. Moreover, because the simplified criteria mandate biopsy material, patients who underwent transplantation for FHF have explant histological material available for analysis in all instances. Only patients with complete demographic, laboratory, and clinical data pertinent to both the simplified and original revised criteria, at the time of their initial diagnosis, were included in this study. In addition, histology was available in every patient. Viral hepatitis was excluded via second-generation and third-generation microparticle enzyme immunoassays for HBV and HCV. For the purposes of this study, overlap syndromes were considered as AIH, as recently reported by Hennes et al. in their description of the simplified criteria for the diagnosis of AIH. 8 Scores derived from the new, simplified criteria and the 1999 IAIHG criteria scores were then calculated. The sensitivity and specificity of these scores for a probable or definite diagnosis of AIH were then calculated, and the positive and negative predictive values were recorded. For patients with FHF, only the relative frequency with which a probable or definite diagnosis of AIH was determined by each score was recorded. It is not possible to calculate the relative sensitivity or specificity for either the 1999 or simplified diagnostic criteria in this clinical context, because it is frequently impossible to ascribe a firm diagnosis in these patients. Diagnosis in these situations is rendered difficult both due to the severity of hepatic insult at presentation (rendering histological evaluation extremely difficult), as well as the immunoparesis commonly seen in the critically ill patient in whom both autoantibodies and/or elevated IgG concentrations may be absent. 14 It is, however, of interest to compare the simplified criteria scores for this patient cohort with the original revised criteria (as the gold standard ) scores in order to document the relative frequencies with which these criteria identify individuals with either a probable or definite diagnosis of AIH. Statistical Analysis. All results are displayed as percentages, or, for continuous variables, median and range. Comparisons of proportions were analyzed by chisquared test or Fisher s exact test if any of the variables equaled less than 5. ROC curves were generated to analyze and compare the accuracy of the simplified and original revised criteria in the diagnosis of AIH. All statistical analysis was performed using the SPSS statistical software package version 14 (SPSS Inc., Chicago, IL). Results A total of 549 patients, comprising 348 females (63%) and 201 males (37%), were identified who had the relevant clinical, laboratory, and histological information available at the time of diagnosis in order to calculate both the 1999 and the simplified IAIHG criteria scores. Of these, 221 patients held a diagnosis of AIH (79% female) with the remaining 328 (53% female) patients having diagnoses of HBV, HCV, PBC, PSC, NASH, AIH/PBC overlap, AIH/PSC overlap, ALD, Wilson s disease, alcohol-related liver disease, hemochromatosis, and drug-induced liver injury. Drug-induced liver injury was related to statins in two patients, nandrolone in two, amoxicillin/ clavulanic acid in two, methylene-dioxy-n-methamphet-

4 HEPATOLOGY, Vol. 50, No. 2, 2009 YEOMAN ET AL. 541 Table 3. Demographic and Laboratory Features with 1999 and Simplified Criteria Scores Across Diagnoses in the Validation Cohort Liver Diagnosis (n) F:M (%) AST Median (range) AST/Alp Ratio Median (range) Autoantibodies (%) IgG Median (range) 1999 Score Simplified Score AIH (221) 79: ( ) 0.13 ( ) ( ) 22 (10 28) 7 (3 8) HBV (51) 27:73 44 ( ) 0.54 ( ) ( ) 0 (0 3) 0 (0 4) HCV (53) 36:64 56 (23 210) 0.53 ( ) ( ) 0 (0 8) 1 (0 4) NASH (49) 57:43 46 (21 937) 0.77 ( ) ( ) 5 (1 13) 2 (2 5) PBC (57) 96:4 94 (28 537) 1.60 ( ) ( ) 1 (0 13) 2 (1 6) PSC (49) 47:53 82 (31 883) 1.60 ( ) ( ) 4 (0 10) 3 (2 6) PBC/AIH variant (9) 100:0 131 ( ) 0.35 ( ) ( ) 14 (7 17) 5 (4 8) PSC/AIH variant (17) 35: ( ) 0.86 ( ) ( ) 13 (9 21) 6 (0 8) Alcohol-related (20) 55:45 62 (27 217) 0.80 ( ) ( ) 1 (0 9) 3 (2 6) Hemochromatosis (7) 14:86 51 (26 180) 0.72 ( ) (12 25) 0 (0 3) 2 (2 4) Drug-induced (9) 44: ( ) 0.56 ( ) ( ) 1 (0 7) 2 (2 5) Wilson s Disease (7) 43:57 80 (32 347) 1.00 ( ) ( ) 5 (1 7) 3 (2 4) FHF (70) 74: ( ) 0.06 ( ) ( ) 7 (0 18) 3 (2 8) Antinuclear antibody, anti smooth muscle, or anti liver-kidney microsomal antibody titers 1:40. AIH, autoimmune hepatitis; ALP, alkaline phosphatase; AST, aspartate aminotransferase; F, female; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV, hepatitis C virus; IgG, immunoglobulin G; M, male; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis. amine (MDMA) in one, synthetic estrogens in one, and enalapril in another. The laboratory and demographic features, in addition to the median simplified and 1999 IAIHG scores by underlying liver diagnosis, are summarized in Table 3. Patients with AIH. The median age at diagnosis of patients with AIH was 46 years (range 5-80). The simplified criteria identified 132 (60%) patients as definite AIH, 73 (33%) patients as probable AIH, and 16 (7%) as not having AIH, in contrast with the 1999 criteria, which for this cohort, identified 220 of 221 (99.5%) patients with definite AIH and only one as probable AIH (1 of %). The sensitivity of the simplified criteria in this cohort was 90% for a probable diagnosis of AIH and 70% for a definite diagnosis. Meanwhile, the specificity was 98% and 100% for probable and definite AIH, respectively. The positive and negative predictive values were 97% and 92% for a probable diagnosis and 100% and 74%, respectively, for a definite diagnosis of AIH. In comparison, evaluation of the 1999 IAIHG criteria demonstrated sensitivities and specificities of 100% and 97% for probable AIH and 99.5% and 98% for definite AIH, respectively. These results are summarized in Table 4. Concordance between the original revised and the simplified scores for a probable or definite diagnosis of AIH was 90% and 61%, respectively. An overall diagnosis of AIH (probable or definite) was recorded in 100% of patients using the 1999 criteria but only in 90% using the simplified criteria. In addition, ROC curves for an overall diagnosis of AIH demonstrated an AUC of (95% confidence interval, ) for the simplified criteria whereas the 1999 criteria had a greater AUC of (95% confidence interval, ) (Fig. 1). Variant Syndromes. Of the 26 patients with a variant syndrome, nine had PBC/AIH and 17 had PSC/AIH. All 26 were treated with prednisolone azathioprine following their diagnosis. Fifteen (58%) were ascribed a diagnosis of AIH (seven probable, eight definite) by the simplified criteria as compared to 24 (92%) patients (15 probable and nine definite) by the 1999 criteria, but this did not reach statistical significance (P 0.17). Patients with the PSC/AIH variant were more likely to be ascribed a probable or definite diagnosis of AIH on the simplified criteria than those with the PBC/AIH variant, although this again did not reach statistical significance (65% versus 44% P 0.42). However, comparison of patients with pure AIH in contrast to those with variant AIH revealed that individuals with pure AIH were significantly more likely to be female (79% versus 58%; P 0.013), icteric at presentation (69% versus 23%; P ), with a higher bilirubin (59 mol/l versus 17 mol/l; Table 4. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) of the Simplified and 1999 IAIHG Criteria for the Diagnosis of AIH Criteria Sensitivity Specificity PPV NPV Simplified Criteria Probable diagnosis AIH (6 7) 90% 98% 97% 92% Definite diagnosis AIH ( 7) 70% 100% 100% 74% Overall Diagnosis AIH ( 6) 90% 98% 97% 92% 1999 Criteria Probable diagnosis AIH (10 15) 100% 97% 96% 100% Definite diagnosis AIH ( 15) 99% 98% 97% 99% Overall Diagnosis AIH ( 10) 100% 97% 97% 99%

5 542 YEOMAN ET AL. HEPATOLOGY, August 2009 Fig. 1. Receiver operating characteristic (ROC) curves for the simplified and 1999 criteria in the diagnosis of AIH. P ), aspartate aminotransferase (AST) (617.5 IU/L versus IU/L; P ) and international normalized ratio (1.21 versus 0.98; P ) at diagnosis. Patients with pure AIH also had higher median simplified criteria biopsy scores (2 versus ) and were more likely to respond to corticosteroids (95% versus 73% P 0.002). Median IgG concentrations trended toward being higher in patients with pure AIH (24.8 g/l versus 19.7 g/l) but did not reach significance (P 0.16), whereas the proportion of patients with positive autoantibodies in titers of either 1:40 or 1:80 did not significantly differ between the two groups. These results are summarized in Table 5. Patients with a False Negative Diagnosis of AIH. Twenty-seven patients (11%) with a clinical diagnosis of AIH or variant AIH were not ascribed a diagnosis of AIH via utilization of the simplified criteria. Having identified significant clinical differences between patients with pure and variant AIH, analysis focused on the majority of patients who have pure AIH. Sixteen patients (7.2%) with pure AIH were not ascribed a diagnosis of AIH on the simplified criteria, whereas the 1999 criteria identified all these as having either probable or definite AIH. When comparing patients ascribed a false negative or a true positive diagnosis of pure AIH, there was no statistical difference between the ratio of females to males, frequency of an icteric presentation, bilirubin, AST, and alkaline phosphatase/ast ratio at presentation. The major differences therefore related to lower concentrations of IgG (median 12.5 versus 25.5 g/dl; P ) and proportion of autoantibody titers of 1:40 (38% versus 84%; P ) or 1:80 (6% versus 72%; P ) among false negative cases. The demographic, laboratory, and clinical characteristics of patients with a false negative or true positive diagnosis of AIH is summarized in Table 6. In view of the reduction in sensitivity for a diagnosis of AIH recorded via the utilization of the simplified criteria, we hypothesized that the addition of responsiveness to corticosteroids might alter the test performance characteristics. We nominally awarded a score of points for a complete response and 0 for no response, and used revised cutoffs of 7 for probable and 8 for a definite diagnosis of AIH. This resulted in improved sensitivity for this cohort from 90% to 96% for a probable diagnosis, and from 70% to 92% for a definite diagnosis of AIH. Subsequently, the sensitivity for an overall diagnosis of AIH increased from 90% to 96% (P ). Patients with a False Positive Diagnosis of AIH. Utilizing the simplified criteria, there were seven false positives out of 328 (2.1%) non-aih patients ascribed a Table 5. Comparison of Demographic, Laboratory, and Clinical Variables at Presentation Between Patients Clinically Diagnosed with Either Pure or Variant AIH in the Study Cohort Variable Pure AIH n 221 Variant AIH n 26 P Value F:M 79:21 58: Icteric 69% 23% Bilirubin 59 (7 1096) 17 (4 246) AST ( ) ( ) ALP:AST ratio 0.14 ( ) ( ) INR 1.21 ( ) 0.98 ( ) Cirrhotic 49% 38% 0.31 Exclusion of viral hepatitis 100% 100% 0.99 Simplified criteria biopsy score 2 (0 2) 1 (0 2) Responders to treatment 95% 73% IgG (g/dl) 24.8 ( ) 19.7 ( ) Autoantibodies 1:40 81% 92% :80 67% 73% 0.56 ALP, alkaline phosphatase; AST, aspartate aminotransferase; F, female; IgG, immunoglobulin G; INR, international normalized ratio; M, male.

6 HEPATOLOGY, Vol. 50, No. 2, 2009 YEOMAN ET AL. 543 Table 6. Comparison of Demographic, Laboratory, and Clinical Variables at Presentation Between False Negative and True Positive Cases of Pure AIH as Ascribed by the Simplified Diagnostic Criteria Variable False Negatives n 16 True Positives n 205 P Value F:M 81:19 79: Icteric 81% 68% 0.40 Bilirubin 97 (11 487) 58 (7 1096) 0.60 AST 612 ( ) 619 ( ) 0.59 ALP:AST ratio 0.11 ( ) 0.16 ( ) 0.84 INR 1.3 ( ) 1.2 ( ) 0.53 Cirrhotic 38% 50% 0.34 Exclusion of viral hepatitis 100% 100% 0.99 Simplified criteria biopsy score 2 (0 2) 2 (0 2) 0.28 Responders to treatment 100% 94% 0.99 IgG (g/dl) 12.5 ( ) 25.5 ( ) Autoantibodies 1:40 38% 84% :80 6% 72% ALP, alkaline phosphatase; AST, aspartate aminotransferase; F, female; IgG, immunoglobulin G; INR, international normalized ratio; M, male. probable diagnosis, and none with a definite diagnosis of AIH. In comparison, the original revised IAIHG criteria ascribed 10 of 328 (3.0%) patients as having probable AIH, and none as having definite AIH. Using the simplified criteria, the seven false positive cases defined as probable AIH comprised four patients with PSC, two with PBC, and one with ALD. The false positive, probable AIH cases, identified by utilization of the original, revised criteria carried diagnoses of NASH in six patients, lone PBC in two patients, and lone PSC in two patients. Patients with Fulminant Hepatic Failure. Seventy patients comprising 52 females (74%) and 18 males (26%) with non acetaminophen induced FHF had the relevant clinical, laboratory, and histological data available to calculate the original revised and simplified criteria scores. In this cohort, the frequency of a diagnosis of AIH, based on the simplified criteria, was 10% for probable (seven patients) and 14% (10 patients) for definite AIH, whereas on the 1999 criteria this equated to 31% (22 patients) and 9% (six patients), respectively. The frequency of an overall diagnosis of AIH was therefore 24% on the simplified criteria and 40% on the 1999 criteria. Only one patient in the seronegative group met criteria for probable AIH, and none met the criteria for definite AIH, via the simplified criteria whereas nine patients met the criteria for probable AIH and none for definite AIH via the 1999 criteria. Prior to the application of either of the 1999 or simplified criteria, 28 of 70 (40%) patients were diagnosed with AIH on clinical grounds, and 42 (60%) were deemed seronegative liver failure. In those diagnosed with AIH by clinical perception, 50% were identified as such by the simplified criteria versus 60% for the 1999 criteria. Concordance between the 1999 and simplified criteria for an overall diagnosis of AIH was 13 of 28 (46%) patients. In four patients, the simplified criteria suggested a definite diagnosis of AIH in whom the 1999 criteria would have graded them as only probable. Additionally, there were 11 instances (16%) in which the 1999 criteria attributed a probable diagnosis of AIH, but the simplified score categorized these individuals as not having AIH. In the non- FHF cohort, this occurred in only 7% of patients. Discussion In this retrospective review of cases from a single, tertiary referral center, the simplified IAIHG criteria clearly demonstrate high specificity for the probable and definite diagnosis of AIH in patients with a nonfulminant course. However, despite sensitivity remaining high for a probable diagnosis it diminishes to only 70% for a definite diagnosis of AIH. Additionally, the concordance between the 1999 and simplified criteria was poor for both probable and definite AIH with the 1999 criteria producing a greater area under the ROC curve, consistent with greater diagnostic accuracy. Of further concern is the lack of sensitivity evident on the simplified criteria for a definite diagnosis of AIH, when it is clearly demonstrated that virtually all patients with AIH (99.5%) in this cohort were classified as definite AIH by the 1999 criteria. A recent, single-center study corroborates the high sensitivity of the simplified criteria for an overall diagnosis of AIH (95%) but notes it to be inferior to the 1999 criteria (100%). Specificity remained high in this retrospective series. 9 In addition, this report suggests that the simplified criteria perform less well in patients with atypical features, a statement with which we concur, based on our own findings. This study, however, appears intended to compare the performance of the 1999 and simplified criteria and, furthermore, does not represent a true validation of the simplified criteria, because an unspecified number of patients in this study were included in the IAIHG simplified criteria cohort reported by Hennes et al. 8 Consequently, the close similarity in sensitivity and specificity between the two reports is entirely to be expected and therefore it is reasonable to conclude that the simplified criteria have not, until now, been independently validated. In the published iteration of the simplified IAIHG criteria, the authors included variant or overlap syndromes as representing AIH for the purposes of their study, because it was deemed important to detect the AIH component in these syndromes. This, however, is a moot point, and open to debate, since variant syndromes may behave differently

7 544 YEOMAN ET AL. HEPATOLOGY, August 2009 over time from classical AIH. 15 In keeping with the simplified IAIHG group report guidelines, 8 we also included variant syndromes as representing AIH, so that a true comparison could be undertaken. Although the sensitivity (100% for 1999 criteria, 93% by simplified criteria) and specificity (97% by 1999 criteria, 98% on simplified criteria) for an overall diagnosis of AIH did not change significantly when variants were excluded, this may be due to a type II error. Possible explanations for the loss of sensitivity evident upon the simplified criteria can be evaluated by comparing the different characteristics of patients with pure AIH or variant AIH. Such analysis reveals that patients with pure AIH were more likely to be icteric, have a higher bilirubin, AST, and international normalized ratio at presentation and a greater likelihood of response to corticosteroids than variant syndrome patients. In view of their different clinical behaviors, this brings into further question whether these individuals should be specifically regarded as having AIH or not for the purposes of assessment by the simplified criteria. If variant syndromes are thus considered as not representing AIH, our experience suggests that the main discriminators between a false negative and true positive diagnosis of AIH via application of the simplified criteria are significantly lower IgG concentrations and frequencies of positive autoantibodies, both at titers of 1:40 and 1:80. That there should be such widespread discrepancies between false negative and false positive cases for two of the four simplified diagnostic criteria is a cause for concern. Furthermore, that the simplified criteria appear less likely to ascribe a diagnosis of AIH than the 1999 criteria, in fulminant and nonfulminant presentations, must also be interpreted in the context of exclusion of other discriminating information such as sex, alcohol and drug history, the presence of cholestatic liver tests, and perhaps most importantly, response to corticosteroids. Such a response to therapy remains a characteristic feature of AIH in clinical practice and, indeed, this finding has been strongly supported in previous incarnations of the diagnostic criteria. 1,5 It is somewhat surprising then, that responsiveness to corticosteroids was omitted from the simplified criteria. Indeed, in this cohort, the application of the simplified criteria was less likely to ascribe a definite diagnosis of AIH than would the 1999 criteria. In such a situation, a trial of corticosteroid therapy would likely be undertaken. Furthermore, the putative addition of responsiveness to corticosteroids significantly increased the sensitivity of a diagnosis of AIH. Importantly, among the non-aih cohort, no additional patient was up-scored to probable or definite AIH via this modification. The utility of the IAIHG scoring systems for diagnosis of AIH have not been specifically studied in patients with FHF, largely due to its low incidence but also as a consequence of the difficulties in ascribing a firm diagnosis to patients with this disorder. However, data published from the United States Acute Liver Failure Study Group, reports that almost 49 of 125 patients (39%) with non acetaminophen induced acute, or subacute liver failure, were due to either AIH (10%) or an indeterminate etiology (29%), with a proportion of these patients likely to have undiagnosed AIH. 16 In support of this statement, and as previously discussed, autoantibodies may be identified in patients with FHF. In the study by Bernal et al., autoantibodies were not identified in any patient with acetaminophen-induced FHF but were present in 43% of non acetaminophen induced etiologies. 10 Moreover, the more specific soluble liver antigen was the most frequent antibody identified in this series. 10 The presence of these AIH-associated autoantibodies in patients with FHF does not, however, prove causation, and indeed may be present in patients with hepatotropic viral infections. 17,18 Nonetheless, the presence of autoantibodies in patients with FHF remains of clinical interest, because many of these patients demonstrate features associated with autoimmunity such as female sex and the presence of human leukocyte antigen DR3 allotype. 19,20 Although there is indeed some overlap between our FHF cohort and that evaluated by Bernal et al., this equated to only nine cases or 13% of the total (W. Bernal, personal communication). Importantly, in our series, the simplified IAIHG criteria appear less sensitive than the gold standard of the 1999 criteria, in ascribing an overall (probable or definite) diagnosis of AIH (24% versus 40%). This was entirely due to 11 patients (16% of this cohort) who were coded as probable AIH via the 1999 criteria but on the simplified criteria were classified as not having AIH. Implicit in this statement, is the observation that no patient who met the simplified criteria for probable AIH was classified as not having AIH on the 1999 criteria. In this clinical context, however, a greater proportion of patients were classified as definite AIH by the simplified criteria than by the 1999 criteria, implying that the newer system has greater specificity but, overall, inferior sensitivity. In clinical practice, this could lead to the diagnosis of AIH not being considered and therefore corticosteroid therapy not being instituted. This has clinical relevance, because the early use of corticosteroids in this setting may improve outcome The application of the simplified and 1999 criteria to patients with FHF should, however, be interpreted with caution, because these criteria were not developed with this clinical presentation in mind, and their utility in this setting is studied for the first time in this report. Nonetheless, because the simplified criteria reported by the IAIHG aims to improve the diag-

8 HEPATOLOGY, Vol. 50, No. 2, 2009 YEOMAN ET AL. 545 nosis of AIH at its initial presentation, it remains important not to ignore the small, but highly significant, proportion of patients with a fulminant course. A further consideration for testing of these criteria relate to a unique population of individuals who have viral liver disease and overlapping features of autoimmunity, either present at disease presentation or precipitated by the use of interferon therapy. We attempted to utilize these criteria in a cohort of 17 patients (12 with chronic HCV and five with chronic HBV) with features of autoimmunity. Among this cohort, 13 had autoimmune features (autoantibodies and/or elevated IgG) prior to antiviral therapy, without features of autoimmune liver disease on biopsy with the remaining four patients developing autoimmune features after therapy. Four patients in this cohort were ascribed a diagnosis of AIH (two being interferon-induced) by clinical perception. Interestingly, the simplified criteria only identified two of these individuals as having AIH superimposed on viral hepatitis, whereas the 1999 criteria identified all four patients, thus corroborating its superiority as a diagnostic tool in challenging cases. In conclusion, in this study we have demonstrated that the simplified IAIHG score identifies the presence of AIH with an extremely high degree of specificity but that sensitivity is lacking, particularly for a definite diagnosis of AIH. This is important because, in a prospectively obtained cohort of patients attending our institution, 99.5% were classified as definite AIH by the 1999 criteria. Additionally, among a separate cohort of patients with FHF, a smaller proportion of patients would be ascribed a diagnosis of AIH on the simplified criteria than on the 1999 criteria, or as attributed by clinical perception. Prospective evaluation of these criteria is required to corroborate these observations. References 1. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. HEPATOLOGY 1993;18: Czaja A, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41: Bianchi FB, Cassani F, Lenzi M, Ballardini G, Muratori L, Giostra F, et al. Impact of International Autoimmune Hepatitis Group scoring system in definition of autoimmune hepatitis - An Italian experience. Dig Dis Sci 1996;41: Toda G, Zeniya M, Watanabe F, Imawari M, Kiyosawa K, Nishioka M, et al. Present status of autoimmune hepatitis in Japan correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol 1997;26: Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31: Heneghan MA, Portmann BC, Norris SM, Willimas R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. HEPATOLOGY 2001;34: Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. HEPATOL- OGY 2008;48: Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. HEPATOLOGY 2008;48: Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 2007;47: Ellis A, Saleh M, Smith H, Portmann B, Gimson A, Williams R. Lateonset hepatic failure: clinical features, serology and outcome following transplantation. J Hepatol 1995;23: Rochling F, Jones W, Chau K, DuCharme L, Mimms LT, Moore B, et al. Acute sporadic non-a, non-b, non-c, non-d, non-e hepatitis. HEPATOL- OGY 1997;25: Kyrlagkitsis I, Cramp M, Smith H, Portmann B, O Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002;49: Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, Mc- Cartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. HEPATOLOGY 1997;25: Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long term outcome and survival. Aliment Pharmacol Ther 2008; 28: Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137: Hansen K, Arnason J, Bridges A. Autoantibodies and common viral illnesses. Semin Arthritis Rheum 1998;27: Niwa Y, Sakane T, Kanoh T, Schichijo S, Wiederhold MD, Yokoyama MM. Transient autoantibodies with elevated complement levels in common viral diseases. Clin Lab Immunol 1984;13: Wigg A, Gunson B, Mutimer D. Outcomes following liver transplantation for seronegative acute liver failure: experience during a 12-year period with more than 100 patients. Liver Transpl 2005;11: Gow P, Hathaway M, Gunson B, Heward J, Mutimer D. Association of fulminant non-a non-b hepatitis with homozygosity for HLA A1 B8- DR3. J Gastroenterol Hepatol 2005;20: Ichai P, Duclos-Valleé J-C, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13: Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. HEPATOLOGY 2002;35: Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95: Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21: Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27: Al-Chalabi T, Underhill J, Portmann BC, McFarlane IG, Heneghan MA. Effects of serum aspartate transaminase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008;6: Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998;17: Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:

In 1993, the International Autoimmune Hepatitis Group

In 1993, the International Autoimmune Hepatitis Group CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION

More information

Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis

Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 131-136, 2014 Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis YI LI, MILIN PENG and GUOZHONG GONG Institute

More information

Diagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems

Diagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems Jikeikai Med J 2011 ; 58 : 89-93 Review Diagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems Mikio Zeniya and Hiroki Takahashi Department of Gastroenterology and Hepatology,

More information

A Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody

A Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF St. Marianna Med. J. Case Report Vol. 32, pp. 33 38, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF A Case

More information

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease

CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months

More information

Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?

Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD

More information

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT GASTROENTEROLOGY 2011;140:1472 1480 Comparability of Probable and Definite Autoimmune Hepatitis by International Diagnostic Scoring Criteria ALBERT J. CZAJA Division of Gastroenterology and Hepatology,

More information

Autoimmune Hepatitis in Clinical Practice

Autoimmune Hepatitis in Clinical Practice 1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure

More information

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner

More information

Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis

Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis Elmer Original Article ress Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis Chijioke Enweluzo a, b, Fahad Aziz a, Amit Mori a Abstract Background: Autoimmune hepatitis

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

Domenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015.

Domenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015. Epatite autoimmune e sindrome da "overlap Domenico ALVARO, MD Sapienza, University of Rome, Italy Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015. AUTOIMMUNE HEPATITIS

More information

Autoimmune hepatitis

Autoimmune hepatitis Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:98 103 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Serologic Markers Do Not Predict Histologic Severity or Response to Treatment in Patients With

More information

What Is the Real Gain After Liver Transplantation?

What Is the Real Gain After Liver Transplantation? LIVER TRANSPLANTATION 15:S1-S5, 9 AASLD/ILTS SYLLABUS What Is the Real Gain After Liver Transplantation? James Neuberger Organ Donation and Transplantation, NHS Blood and Transplant, Bristol, United Kingdom;

More information

News. Laboratory. CHANGES IN CARDIAC TROPONIN I REPORTING Gene Shaw, MD, Annu Khajuria, PhD. Inside This Issue

News. Laboratory. CHANGES IN CARDIAC TROPONIN I REPORTING Gene Shaw, MD, Annu Khajuria, PhD. Inside This Issue Laboratory News Inside This Issue CHANGES IN CARDIAC TROPONIN I REPORTING...1 FOUR NEW SEROLOGY TESTS FOR AUTOIMMUNE LIVER DISEASES...3 INSULIN LIKE GROWTH FACTOR-1 (IGF-1) METHOD CHANGES...6 CHANGES IN

More information

Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the acute type

Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the acute type Q J Med 2004; 97:407 412 doi:10.1093/qjmed/hch072 Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the acute type R. FERRARI 1, G. PAPPAS 1, D. AGOSTINELLI 1,

More information

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? 22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical

More information

Update on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC

Update on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Update on Autoimmune Liver Disease Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth

More information

Autoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018

Autoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018 Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is

More information

Serologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I

Serologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.

More information

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:

More information

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Autoimmune Hepatitis: Defining the need for Liver Transplantation Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background

More information

Autoimmune hepatitis (AIH) is a rare disease, yet it. Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is a rare disease, yet it. Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:625 631 Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis WILLIAM R. KESSLER,* OSCAR W. CUMMINGS, GEORGE ECKERT, NAGA CHALASANI,*

More information

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions

More information

Clinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population

Clinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases BRIEF REPORT Clinical characteristics and response to therapy of autoimmune hepatitis

More information

Novel Therapies in Autoimmune Hepatitis

Novel Therapies in Autoimmune Hepatitis Novel Therapies in Autoimmune Hepatitis Paul W. Rassam,MD Ass. Clinical Professor of Medicine Div. of Gastroenterology and Hepatology St George Hospital University Medical Center University of Balamand

More information

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis Clin J Gastroenterol (2012) 5:141 145 DOI 10.1007/s28-012-0295-4 CASE REPORT Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and

More information

Autoimmune hepatitis (AIH) is a chronic progressive. Predictors of Poor Outcome in Patients With Autoimmune Hepatitis: A Population-Based Study

Autoimmune hepatitis (AIH) is a chronic progressive. Predictors of Poor Outcome in Patients With Autoimmune Hepatitis: A Population-Based Study Predictors of Poor Outcome in Patients With Autoimmune Hepatitis: A Population-Based Study Jing Hieng Ngu, 1,2 Richard Blair Gearry, 1,2 Chris Miles Frampton, 2 and Catherine A.M. Stedman 1,2 Autoimmune

More information

Features of Autoimmune Hepatitis in Egyptian Children

Features of Autoimmune Hepatitis in Egyptian Children Med. J. Cairo Univ., Vol. 78, No. 1, March: 107-112, 2010 www.medicaljournalofcairouniversity.com Features of Autoimmune Hepatitis in Egyptian Children NEHAL EL-KOOFY, M.D.; MONA FAHMY, M.D.*; MONA AZIZ,

More information

Introduction. Kaoru Omori 1 Masahiro Kan 1. Kanako Yoshida

Introduction. Kaoru Omori 1 Masahiro Kan 1. Kanako Yoshida Clin J Gastroenterol (2016) 9:312 318 DOI 10.1007/s28-016-0676-1 CASE REPORT Familial occurrence of autoimmune liver disease with overlapping features of primary biliary cholangitis and autoimmune hepatitis

More information

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue

More information

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis

More information

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di

More information

Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions

Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions Gut and Liver, Vol. 10, No. 2, March 2016, pp. 177-203 Review Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions Albert J. Czaja Division of Gastroenterology and Hepatology,

More information

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently

More information

Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center

Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center GASTROENTEROLOGY 2011;140:1980 1989 Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center BARBARA HOEROLDT, ELAINE MCFARLANE,* ASHA DUBE, PANDURANGAN BASUMANI, MOHAMMED

More information

Hépatopathies auto-immunes

Hépatopathies auto-immunes 16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois

More information

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests

More information

A utoimmune hepatitis (AIH) is a rare disease occurring

A utoimmune hepatitis (AIH) is a rare disease occurring 713 LIVER DISEASE Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin T Zolfino, M A Heneghan, S Norris, P M Harrison, B C Portmann, I G McFarlane... See

More information

Histopathology of De Novo Autoimmune Hepatitis

Histopathology of De Novo Autoimmune Hepatitis LIVER TRANSPLANTATION 18:811-818, 2012 ORIGINAL ARTICLE Histopathology of De Novo Autoimmune Hepatitis Ananya Pongpaibul, 1 Robert S. Venick, 2 Sue V. McDiarmid, 3 and Charles R. Lassman 4 1 Department

More information

Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis

Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis Furumoto et al. BMC Gastroenterology (2015) 15:144 DOI 10.1186/s12876-015-0360-9 RESEARCH ARTICLE Open Access Evaluation of the role of HLA-DR antigens in Japanese type 1 autoimmune hepatitis Yohei Furumoto

More information

Autoimmune Liver Diseases

Autoimmune Liver Diseases 2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012

More information

Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults

Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults CASE REPORT Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults Go Igarashi 1, Tetsu Endo 1, Kenichiro Mikami 1, Naoya Sawada 1,RyuSatake 1, Rie Ohta 1, Juichi Sakamoto

More information

.03). (42% 13%, P.006). HLA DR3

.03). (42% 13%, P.006). HLA DR3 Distinctive Clinical Phenotype and Treatment Outcome of Type 1 Autoimmune Hepatitis in the Elderly Albert J. Czaja 1 and Herschel A. Carpenter 2 Autoimmune hepatitis is classically a disease of young women.

More information

Drug-induced immune-mediated liver injury is. Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis

Drug-induced immune-mediated liver injury is. Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis Drug-Induced Autoimmune Hepatitis: Clinical Characteristics and Prognosis Einar Björnsson, 1,2 Jayant Talwalkar, 2 Sombat Treeprasertsuk, 2 Patrick S. Kamath, 2 Naoki Takahashi, 3 Schuyler Sanderson, 4

More information

Long-term Treatment Outcomes for Autoimmune Hepatitis in Korea

Long-term Treatment Outcomes for Autoimmune Hepatitis in Korea J Korean Med Sci 21; 25: 54-6 ISSN 111-8934 DOI: 1.3346/jkms.21.25.1.54 Long-term Treatment Outcomes for Autoimmune Hepatitis in Korea Immunosuppressive therapy can improve clinical, biochemical and histological

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic

More information

SIRS Score Reflects Clinical Features of Non-Acetaminophen-Related Acute Liver Failure with Hepatic Coma

SIRS Score Reflects Clinical Features of Non-Acetaminophen-Related Acute Liver Failure with Hepatic Coma ORIGINAL ARTICLE SIRS Score Reflects Clinical Features of Non-Acetaminophen-Related Acute Liver Failure with Hepatic Coma Yasuhiro Miyake, Tetsuya Yasunaka, Fusao Ikeda, Akinobu Takaki, Kazuhiro Nouso

More information

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Hwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD

Hwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary

More information

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients

Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients Hepat Mon. 2012;12(2):92-99. DOI: 10.5812/hepatmon.808 KOWSAR www.hepatmon.com Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients 1,2 Zinab Malekzadeh, Sepideh Haghazali

More information

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis

21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov

More information

Diagnostic utility of IgG and IgM immunohistochemistry in autoimmune liver disease

Diagnostic utility of IgG and IgM immunohistochemistry in autoimmune liver disease Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v16.i4.453 World J Gastroenterol 2010 January 28; 16(4): 453-457 ISSN 1007-9327 (print) 2010 Baishideng. All rights

More information

Aldo Torre., 2011; 10 (1): 28-32

Aldo Torre., 2011; 10 (1): 28-32 28 ORIGINAL ARTICLE January-March, Vol. 10 No.1, 2011: 28-32 Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis

More information

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis

Case #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis 45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)

More information

Hépatite auto-immune. aigue sévère

Hépatite auto-immune. aigue sévère 9 eme journée des Centres de Reference et de Compétence des Maladies Inflammatoires des Voies Biliaires et des Hépatites Auto-Immune (MIVB-H) llaborat ions des équipes impliquées dans l' ex plora char

More information

Autoimmune Hepatitis: Histopathology

Autoimmune Hepatitis: Histopathology REVIEW Autoimmune Hepatitis: Histopathology Stephen A. Geller M.D.*, Autoimmune hepatitis (AIH), a chronic hepatic necroinflammatory disorder, occurs mostly in women. AIH is characterized by prominent

More information

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal

More information

Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis

Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis SPECIAL ARTICLE Annals of Gastroenterology (2019) 32, 1-24 Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis George N. Dalekos a,b, John Koskinas c, George

More information

British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis

British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis 1 Liver Unit, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK 2 Institute of Liver Studies, King s College Hospital NHS Foundation Trust, London, UK Correspondence to Dr Dermot Gleeson, P

More information

Autoimmune hepatitis: an approach to disease understanding and management

Autoimmune hepatitis: an approach to disease understanding and management British Medical Bulletin, 2015, 114:181 191 doi: 10.1093/bmb/ldv021 Advance Access Publication Date: 20 May 2015 Autoimmune hepatitis: an approach to disease understanding and management Margaret Corrigan,

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Autoimmune hepatitis. Recent advances. Dominique-Charles VALLA

Autoimmune hepatitis. Recent advances. Dominique-Charles VALLA Autoimmune hepatitis Recent advances Dominique-Charles VALLA The field of autoimmune hepatitis has been quite active since the last update on the topic at the Day of Hepatology of Beaujon Hospital in 2002.

More information

Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease

Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA

More information

Presentation and mortality of primary biliary cirrhosis in older patients

Presentation and mortality of primary biliary cirrhosis in older patients Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET

More information

Autoimmune hepatitis (AIH) is an organ-specific. Long-term Outcome of Japanese Patients With Type 1 Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is an organ-specific. Long-term Outcome of Japanese Patients With Type 1 Autoimmune Hepatitis Long-term Outcome of Japanese Patients With Type 1 Autoimmune Hepatitis Kaname Yoshizawa, 1,4 Akihiro Matsumoto, 1 Tetsuya Ichijo, 1 Takeji Umemura, 1 Satoru Joshita, 1 Michiharu Komatsu, 1 Naoki Tanaka,

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

Chronic liver allograft dysfunction. An unsolved problem

Chronic liver allograft dysfunction. An unsolved problem Chronic liver allograft dysfunction An unsolved problem % patient survival % patient survival 100 Kaplan-Meier estimates by sex and age group 100 90 90 80 80 70 70 60 60 50 50 40 40 30 20 10 Males Females

More information

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019 LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

PBC features and management in the era of UDCA and Budesonide

PBC features and management in the era of UDCA and Budesonide PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More

More information

Guideline Summary NGC-8005

Guideline Summary NGC-8005 NGC banner Guideline Summary NGC-8005 Guideline Title Diagnosis and management of autoimmune hepatitis. Bibliographic Source(s) Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling

More information

budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd

budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd 10 April 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

There is no specific diagnostic test for autoimmune

There is no specific diagnostic test for autoimmune Long-Term Follow-Up of Antimitochondrial Antibody Positive Autoimmune Hepatitis Conor O Brien, 1 Supriya Joshi, 1 Jordan J. Feld, 2 Maha Guindi, 3 Hans P. Dienes, 4 and E. Jenny Heathcote 1 Antimitochondrial

More information

Original Article. Comparison of Autoimmune Hepatitis in Elderly and Nonelderly Patients

Original Article. Comparison of Autoimmune Hepatitis in Elderly and Nonelderly Patients J. Kyoto Pref. Univ. Med. 127 Original Article Comparison of Autoimmune Hepatitis in Elderly and Nonelderly Patients Hideki Fujii, Hiroyuki Kimura, Toru Kadono, Kohei Asaeda, Reo Kobayashi Takuma Yoshida,

More information

Title: Anti-programmed cell death-1 antibody as a new serological marker for type

Title: Anti-programmed cell death-1 antibody as a new serological marker for type 1 Title: Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. Short running title: Anti-PD-1 antibody and type 1 AIH. Authors: Kazuyuki Matsumoto, Yasuhiro

More information

Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.

Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,

More information

Original Article. Clinicopathological profile and management of severe autoimmune hepatitis

Original Article. Clinicopathological profile and management of severe autoimmune hepatitis Tropical Gastroenterology 2014;35(1):25 31 Original Article Clinicopathological profile and management of severe autoimmune hepatitis Jeyamani Ramachandran, 1 Sajith KG, 1 Sandip Pal, 1 Jiffy Rasak VA,

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:339 345 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Prognostic Implications of Lactate, Bilirubin, and Etiology in German Patients With Acute Liver

More information

Although autoimmune hepatitis (AIH) typically. Autoimmune Acute Liver Failure: Proposed Clinical and Histological Criteria

Although autoimmune hepatitis (AIH) typically. Autoimmune Acute Liver Failure: Proposed Clinical and Histological Criteria AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Autoimmune Acute Liver Failure: Proposed Clinical and Histological Criteria R. Todd Stravitz, 1 * Jay H. Lefkowitch, 2 * Robert J. Fontana, 3 M. Eric Gershwin,

More information

King Abdul-Aziz University Hospital (KAUH) is a tertiary

King Abdul-Aziz University Hospital (KAUH) is a tertiary Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors

More information

Optimal management of auto-immune

Optimal management of auto-immune collaborations des équipes impliquées dans l' explorati en charge des ef ets indésirables des immunothérapies INSCRIPTIONS BLIC : cialistes d organe, Chercheur s, ovigilants ns l es toxicités es anti-cancéreuses.

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt

More information

Sojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh

Sojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh Original article Annals of Gastroenterology (2013) 26, 1-5 Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute

More information

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM EVALUATION OF LIVER FUNCTION R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM METABOLIC FUNCTION

More information

EVALUATION OF ABNORMAL LIVER TESTS

EVALUATION OF ABNORMAL LIVER TESTS EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical

More information

Risk stratification in PBC

Risk stratification in PBC Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive

More information

Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos Gatselis, George N. Dalekos, Kalliopi Zachou

Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos Gatselis, George N. Dalekos, Kalliopi Zachou Severe acute non-a, non-b, non-c hepatitis with autoimmune features: Consider acute hepatitis E virus (HEV) infection not just autoimmune hepatitis (AIH) Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos

More information

Liver disease affecting children and teenagers with transition into adult care

Liver disease affecting children and teenagers with transition into adult care Liver disease affecting children and teenagers with transition into adult care Rachel Brown Queen Elizabeth Hospitals Birmingham and Birmingham Children s Hospital How different is medical liver biopsy

More information

Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management

Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management Drugs Aging https://doi.org/10.1007/s40266-018-0556-0 THERAPY IN PRACTICE Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management Syed Rizvi 1 Samer Gawrieh 2 Ó Springer International

More information

A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis

A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1036 1040 A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis JONATHAN T. HLIVKO, MITCHELL L. SHIFFMAN, R.

More information

Current Concepts in the Management and Treatment of PBC & PSC

Current Concepts in the Management and Treatment of PBC & PSC Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes

More information